(Q39239280)

English

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.

scientific article published on 24 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

tumour xenograft

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

M Virginia C L Appleyard

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sheila Sharp

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Ian N Fleming

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Karen Murray

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alastair M Thompson

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

24 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

71

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

473-480

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23178956%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

https://scigraph.springernature.com/pub.10.1007/s00280-012-2032-6

0 references

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Fibronectin stimulates endothelial cell 18F-FDG uptake through focal adhesion kinase-mediated phosphatidylinositol 3-kinase/Akt signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Tumour glycolysis: the many faces of HIF.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Quantitative 31P magnetic resonance spectroscopy of the human breast at 7 T.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2032-6

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39239280&oldid=1640157641"